Results of a Second Year of Therapy with the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty

Background. Gonadotropin releasing hormone analogs (GnRHas) are standard of care for central precocious puberty (CPP). The histrelin subcutaneous implant is safe and effective in the treatment of CPP for one year. Objective. The study evaluates a second year of therapy in children with CPP who recei...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Rahhal, Samar, Clarke, William L., Kletter, Gad B., Lee, Peter A., Neely, E. Kirk, Reiter, Edward O., Saenger, Paul, Shulman, Dorothy, Silverman, Lawrence, Eugster, Erica A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi Publishing Corporation 2009
Aiheet:
Clinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2777002/
https://ncbi.nlm.nih.gov/pubmed/19956699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2009/812517
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia